Project Grant R43HL186091

The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients.

The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while FDA-approved endobronchial valves exclude approximately 90 percent of emphysema patients due to fissure integrity requirements. Prior endobronchial steam ablation attempts generated high adverse event rates from uncontrolled thermal delivery into healthy lung tissue. This Phase I SBIR award funds development of a cooled radiofrequency approach designed to enable controlled, safer lung volume reduction in patient populations ineligible for existing treatments.

Coridea, LLC, a New York City-based small disadvantaged business, develops minimally invasive medical device technologies. The company holds prior NHLBI grants and support from the National Institute on Drug Abuse and National Institute of General Medical Sciences for related interventional and device research.

The period of performance runs from September 1, 2026, through August 31, 2027. Work is performed in New York, New York. The SBIR program evaluation criteria assess technological innovation, commercial potential, feasibility of Phase I objectives, and qualifications of the investigator team.